Physician profile
Robert L Lott
NPI 1952530222
$4,115.90
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $311 · 2021: $1,009 · 2022: $502 · 2023: $687 · 2024: $547 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.12 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.76 | 2019-2025 | |
| Janssen Biotech, INC. | $525.17 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $431.95 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $320.33 | 2021-2024 | Libtayo |
| Genzyme Corporation | $277.31 | 2020-2024 | |
| Ucb, INC. | $198.63 | 2021-2025 | Bimzelx |
| Incyte Corporation | $191.03 | 2022-2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $141.45 | 2019-2022 | |
| Amgen INC. | $113.89 | 2021-2023 | Otezla |
| Pfizer INC. | $99.19 | 2020-2023 | |
| Galderma Laboratories, L.P. | $71.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.27 | 2021-2022 | |
| Organogenesis INC. | $60.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.88 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $41.87 | 2022-2023 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $36.87 | 2019-2020 | |
| Celgene Corporation | $32.40 | 2019 | |
| Mimedx Group, INC. | $24.88 | 2024 | |
| Arcutis Biotherapeutics, INC. | $16.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.